TABLE OF CONTENTS
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET 17
1.4 LIMITATIONS 20
1.5 MARKETS COVERED 20
2 MARKET SEGMENTATION 23
2.1 MARKETS COVERED 23
2.2 GEOGRAPHICAL SCOPE 24
2.3 YEARS CONSIDERED FOR THE STUDY 24
2.4 CURRENCY AND PRICING 24
2.5 DBMR TRIPOD DATA VALIDATION MODEL 25
2.6 MULTIVARIATE MODELLING 28
2.7 PRODUCT TYPE LIFELINE CURVE 28
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.9 DBMR MARKET POSITION GRID 30
2.10 MARKET END USER COVERAGE GRID 31
2.11 VENDOR SHARE ANALYSIS 32
2.12 SECONDARY SOURCES 33
2.13 ASSUMPTIONS 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHTS 37
4.1 PESTEL 38
4.2 PORTER'S 39
4.3 INDUSTRIAL INSIGHTS: 40
5 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: REGULATIONS 41
5.1 REGULATION IN U.S. 41
5.1.1 GUIDELINES- 41
5.2 REGULATION IN CANADA 42
5.2.1 GUIDELINES FOR THE MANUFACTURERS: 42
5.3 REGULATION IN MEXICO 43
5.3.1 GUIDELINES FOR THE MANUFACTURERS: 43
6 MARKET OVERVIEW 44
6.1 DRIVERS 46
6.1.1 INCREASING GERIATRIC POPULATION ALONG WITH RISING PREVALENCE OF CARDIAC DISEASES 46
6.1.2 PRESENCE OF FAVOURABLE REIMBURSEMENT POLICIES 46
6.1.3 CHANGING LIFESTYLE TRIGGERS THE DEVELOPMENT OF CARDIOVASCULAR DISEASES 47
6.2 RESTRAINTS 47
6.2.1 HIGH COST OF LVAD IMPLANTATION AND TREATMENT 47
6.2.2 COMPLICATIONS AND RISKS ASSOCIATED WITH LVAD 48
6.3 OPPORTUNITIES 49
6.3.1 INCREASE IN HEALTHCARE EXPENDITURE 49
6.3.2 INCREASE IN MINIMALLY INVASIVE PROCEDURE 49
6.3.3 INCREASING SHORTAGE OF ORGAN DONORS 49
6.3.4 TECHNOLOGICAL ADVANCEMENTS IN LEFT VENTRICULAR ASSIST DEVICES 50
6.4 CHALLENGES 50
6.4.1 ONGOING COVID-19 50
6.4.2 INCREASE IN PRODUCT RECALL 50
7 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE 52
7.1 OVERVIEW 53
7.2 HEART PUMP 56
7.3 CONTROLLER 56
7.4 BATTERIES 57
7.4.1 RECHARGEABLE 58
7.4.2 NON-RECHARGEABLE 58
7.5 WIRES 58
8 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY 59
8.1 OVERVIEW 60
8.2 BRIDGE-TO-TRANSPLANT (BTT) THERAPY 63
8.2.1 HEART PUMP 63
8.2.2 CONTROLLER 64
8.2.3 BATTERIES 64
8.2.4 WIRES 64
8.3 DESTINATION THERAPY 64
8.3.1 HEART PUMP 65
8.3.2 CONTROLLER 65
8.3.3 BATTERIES 65
8.3.4 WIRES 65
8.4 BRIDGE-TO-CANDIDACY (BTC) THERAPY 65
8.4.1 HEART PUMP 66
8.4.2 CONTROLLER 66
8.4.3 BATTERIES 66
8.4.4 WIRES 66
8.5 BRIDGE-TO-RECOVERY (BTR) THERAPY 66
8.5.1 HEART PUMP 67
8.5.2 CONTROLLER 67
8.5.3 BATTERIES 67
8.5.4 WIRES 68
9 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP 69
9.1 OVERVIEW 70
9.2 ADULT 73
9.2.1 19-39 YEARS 73
9.2.2 40-59 YEARS 73
9.2.3 60-79 YEARS 73
9.2.4 ABOVE 80 YEARS 74
9.3 PEDIATRIC 74
10 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY GENERATION 75
10.1 OVERVIEW 76
10.2 SECOND GENERATION DEVICES 79
10.3 THIRD GENERATION DEVICES 79
10.4 FIRST GENERATION DEVICES 80
11 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DESIGN 81
11.1 OVERVIEW 82
11.2 AXIAL 85
11.3 CENTRIFUGAL 85
12 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION 86
12.1 OVERVIEW 87
12.2 CONGESTIVE HEART FAILURE 90
12.2.1 HEART PUMP 90
12.2.2 CONTROLLER 90
12.2.3 BATTERIES 90
12.2.4 WIRES 90
12.3 CONGENITAL HEART DISEASE 91
12.3.1 HEART PUMP 91
12.3.2 CONTROLLER 91
12.3.3 BATTERIES 92
12.3.4 WIRES 92
12.4 MYOCARDITIS 92
12.4.1 HEART PUMP 92
12.4.2 CONTROLLER 93
12.4.3 BATTERIES 93
12.4.4 WIRES 93
12.5 CARDIAC ARREST 93
12.5.1 HEART PUMP 94
12.5.2 CONTROLLER 94
12.5.3 BATTERIES 94
12.5.4 WIRES 94
12.6 FAMILIAL ARRHYTHMIAS AND ARRHYTHMIC CARDIOMYOPATHIES 94
12.6.1 HEART PUMP 95
12.6.2 CONTROLLER 95
12.6.3 BATTERIES 95
12.6.4 WIRES 95
12.7 ADVANCED HEART FAILURE 96
12.7.1 HEART PUMP 96
12.7.2 CONTROLLER 96
12.7.3 BATTERIES 96
12.7.4 WIRES 97
12.8 OTHERS 97
13 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY DURABILITY 98
13.1 OVERVIEW 99
13.2 LONG-TERM 102
13.3 INTERMEDIATE-TERM 102
13.4 SHORT-TERM 102
14 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY PULSE TYPE 104
14.1 OVERVIEW 105
14.2 NONPULSATILE 108
14.3 PULSATILE 108
15 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY END USER 109
15.1 OVERVIEW 110
15.2 HOSPITAL 113
15.3 CARDIAC CATH LABORATORIES 113
15.4 SPECIALTY CLINICS 114
15.5 OTHERS 114
16 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY DISTRIBUTION CHANNEL 115
16.1 OVERVIEW 116
16.2 DIRECT TENDER 119
16.3 RETAIL SALES 119
16.4 OTHERS 120
17 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY NORTH AMERICA 121
17.1 NORTH AMERICA 121
17.1.1 U.S. 127
17.1.2 CANADA 133
17.1.3 MEXICO 139
18 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: COMPANY LANDSCAPE 145
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 145
19 SWOT ANALYSIS 146
20 COMPANY PROFILE 147
20.1 ABIOMED 147
20.1.1 COMPANY SNAPSHOT 147
20.1.2 REVENUE ANALYSIS 147
20.1.3 COMPANY SHARE ANALYSIS 148
20.1.4 PRODUCT PORTFOLIO 148
20.1.5 RECENT DEVELOPMENTS 149
20.1.5.1 FDA APPROVAL 149
20.1.5.2 FDA APPROVAL 149
20.2 ABBOTT 150
20.2.1 COMPANY SNAPSHOT 150
20.2.2 REVENUE ANALYSIS 150
20.2.3 COMPANY SHARE ANALYSIS 151
20.2.4 PRODUCT PORTFOLIO 151
20.2.5 RECENT DEVELOPMENTS 151
20.2.5.1 SUPPLY INCREMENT 151
20.2.5.2 BREAK THROUGH DEVICE DESIGNATION 152
20.3 BERLIN HEART 153
20.3.1 COMPANY SNAPSHOT 153
20.3.2 COMPANY SHARE ANALYSIS 153
20.3.3 PRODUCT PORTFOLIO 154
20.3.4 RECENT DEVELOPMENT 154
20.3.4.1 PRODUCT APPROVAL 154
20.4 SAFT (A SUBSIDIARY OF TOTALENERGIES) 155
20.4.1 COMPANY SNAPSHOT 155
20.4.2 REVENUE ANALYSIS 155
20.4.3 COMPANY SHARE ANALYSIS 156
20.4.4 PRODUCT PORTFOLIO 156
20.4.5 RECENT DEVELOPMENT 156
20.4.5.1 PARTNERSHIP 156
20.5 JARVIK HEART, INC. 157
20.5.1 COMPANY SNAPSHOT 157
20.5.2 COMPANY SHARE ANALYSIS 157
20.5.3 PRODUCT PORTFOLIO 157
20.5.4 RECENT DEVELOPMENT 158
20.5.4.1 FDA APPROVAL 158
20.6 CORWAVE SA 159
20.6.1 COMPANY SNAPSHOT 159
20.6.2 PRODUCT PORTFOLIO 159
20.6.3 RECENT DEVELOPMENT 159
20.6.3.1 EXPANSION 159
20.7 EVAHEART, INC 160
20.7.1 COMPANY SNAPSHOT 160
20.7.2 PRODUCT PORTFOLIO 160
20.7.3 RECENT DEVELOPMENT 160
20.7.3.1 PRODUCT TRIAL 160
21 QUESTIONNAIRE 161
22 RELATED REPORTS 166

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.